<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03580122</url>
  </required_header>
  <id_info>
    <org_study_id>NL49929.068.17</org_study_id>
    <nct_id>NCT03580122</nct_id>
  </id_info>
  <brief_title>The Effect of Arginine on Classic Galactosemia</brief_title>
  <acronym>ARGALT</acronym>
  <official_title>Does Arginine Enhance Galactose Oxidative Capacity in Classic Galactosemia: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Ziekenhuis Maastricht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Ziekenhuis Maastricht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Classic galactosemia is a rare inherited metabolic disease that presents in
      neonatal patients with a life-threatening multi-organ toxic syndrome. Although the current
      standard of care - a galactose-restricted diet - quickly relieves the severe neonatal
      clinical picture, it fails to prevent brain and gonadal sequelae. There is a need for new
      therapeutic strategies.

      As arginine is an amino acid that is therapeutically widely used with no side effects
      described, we propose to use it in a pilot-clinical study. We aim to evaluate the effects of
      arginine in classic galactosemia patients, in order to determine its potential therapeutic
      role in this disease.

      Objective: To evaluate the possible effect of arginine on the whole body galactose oxidative
      capacity in classic galactosemia patients.

      Study design: Interventional pilot-clinical study with pre-post single arm design.

      Study population: We aim to include 5 classic galactosemia adult patients homozygous for the
      p.Q188R mutation.

      Intervention: All participants will receive arginine in the form of Asparten Â® (arginine
      aspartate) during 1 month, by oral administration.

      The main study parameter is whole body galactose galactose oxidative capacity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 5, 2017</start_date>
  <completion_date type="Actual">September 5, 2018</completion_date>
  <primary_completion_date type="Actual">January 12, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>whole body galactose oxidative capacity</measure>
    <time_frame>6 hours</time_frame>
    <description>Whole body galactose oxidative capacity is breathing test that quantifies [1-13C]-galactose conversion into 13CO2, thus allowing to delineate the exact extent of impaired galactose metabolism, providing clear information on a patient's ability to oxidize galactose.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Classic Galactosemia</condition>
  <arm_group>
    <arm_group_label>Asparten</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Asparten (arginine aspartate) 5000mg/10mL 3x/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arginine Aspartate</intervention_name>
    <description>Asparten</description>
    <arm_group_label>Asparten</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Classic galactosemia patient homozygous for the p.Q188R mutation, diagnosed by GALT
             enzyme activity assay and GALT gene mutation analysis

          -  Eighteen years of age or older

          -  Capable of giving informed consent

        Exclusion Criteria:

          -  Urea cycle disorders (assessed by post prandial amino acid profile in blood)

          -  Increased level of plasma uric acid

          -  Patients experiencing acute illness of classic galactosemia

          -  Pregnant women (or considering getting pregnant) or breastfeeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Maastricht</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>June 5, 2018</study_first_submitted>
  <study_first_submitted_qc>July 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2018</study_first_posted>
  <last_update_submitted>September 26, 2018</last_update_submitted>
  <last_update_submitted_qc>September 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Ziekenhuis Maastricht</investigator_affiliation>
    <investigator_full_name>Ana Coelho</investigator_full_name>
    <investigator_title>Coordinating Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Galactosemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

